News
-
Enlivex Completes Patient Enrollment In Its Phase I/II Clinical Trial
1/24/2012
Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.
-
Roche´s GS Junior Sequencing System Used In Research On Personalized Tumor Treatment
1/18/2012
The Center for Human Genetics and Laboratory Medicine Dr. Klein and Dr. Rost, and IMGM Laboratories, both located in Martinsried Germany, reported using the Roche GS Junior Benchtop System to sequence clinically relevant exons and identify genomic variations in solid tumors treated with an antibody-based medicine.
-
Oxygen Biotherapeutics To Begin Clinical Study To Determine Efficacy Of Dermacyte® In Relieving Histamine Induced Pruritus
1/10/2012
Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) announced today that enrollment for the company's first dermatological study will begin later this month at St. John's Medical College Hospital in Bangalore, India.
-
Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors
1/10/2012
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.
-
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease
12/28/2011
Abbott recently announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking).
-
Isis Adds Three New Drugs To Its Development Pipeline
12/16/2011
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx.
-
Roche Announces Positive Results Of Pivotal Phase III Study With Pertuzumab In HER2-Positive Metastatic Breast Cancer
12/12/2011
Roche recently announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab.
-
MIT Research: Proteins Linked To Longevity May Be Involved In Mood Control
12/12/2011
Over the past decade, MIT biologist Leonard Guarente and others have shown that very-low-calorie diets provoke a comprehensive physiological response that promotes survival, all orchestrated by a set of proteins called sirtuins. By Anne Trafton, MIT
-
New Data Confirms Novartis Drug Afinitor Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
12/9/2011
The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), abstract #S3-7.
-
Roche NimbleGen And BGI Develop Advanced MHC Region Capture Technology For Human Disease And Biomedical Research
11/30/2011
Roche NimbleGen, Inc. and BGI, the world’s largest genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology based on NimbleGen SeqCap EZ Choice Library, a revolutionary process for the enrichment of the MHC region.
This website uses cookies to ensure you get the best experience on our website. Learn more